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Abstract
IL-22 is a Th17/Th22 cytokine that is increased in asthma. However, recent animal studies showed controversial findings in
the effects of IL-22 in allergic asthma. To determine the role of IL-22 in ovalbumin-induced allergic inflammation we
generated inducible lung-specific IL-22 transgenic mice. Transgenic IL-22 expression and signaling activity in the lung were
determined. Ovalbumin (OVA)-induced pulmonary inflammation, immune responses, and airway hyperresponsiveness
(AHR) were examined and compared between IL-22 transgenic mice and wild type controls. Following doxycycline (Dox)
induction, IL-22 protein was readily detected in the large (CC10 promoter) and small (SPC promoter) airway epithelial cells.
IL-22 signaling was evidenced by phosphorylated STAT3. After OVA sensitization and challenge, compared to wild type
littermates, IL-22 transgenic mice showed decreased eosinophils in the bronchoalveolar lavage (BAL), and in lung tissue,
decreased mucus metaplasia in the airways, and reduced AHR. Among the cytokines and chemokines examined, IL-13 levels
were reduced in the BAL fluid as well as in lymphocytes from local draining lymph nodes of IL-22 transgenic mice. No effect
was seen on the levels of serum total or OVA-specific IgE or IgG. These findings indicate that IL-22 has immune modulatory
effects on pulmonary inflammatory responses in allergen-induced asthma.
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Introduction
Allergen-induced pulmonary responses in asthma are charac-
terized by eosinophil infiltration, mucus hypersecretion, airway
hyperreactivity and bronchoconstriction. Th2 cytokines, IL-4 and
IL-13, play a central role in orchestrating these responses, whereas
Th1 cytokine IFN-c may have opposing effects [1–4]. Further-
more, the Th17 cytokine IL-17A is critical in the pathogenesis of
severe asthma [4,5]. Recently, a novel Th17/Th22 cytokine, IL-
22, was found to have immune modulatory effects on pulmonary
allergic inflammation [6–8].
Th17/Th22 cells mainly secrete IL-17A, IL-17F and IL-22
[9,10]. Both IL-17 and IL-22 have been found to have a major
impact in epithelial cells in various tissues and are key regulators of
homeostasis and epithelial barrier function. However, IL-22 also
promotes tissue inflammation [11,12]. Furthermore, the immu-
nological effects of these cytokines vary in different contexts. It has
been recognized that IL-17 has an important role in the
recruitment of neutrophils in response to bacterial infection and
a potential role in severe asthma, which may contribute to
corticosteroid resistance [4,13]. However, the immune modulatory
effects of IL-22 in allergen-induced lung inflammation are not well
understood.
IL-22, a member of the IL-10 family cytokines, plays critical
roles in innate and adaptive immunity. In the gastrointestinal tract,
innate lymphoid cells (ILCs) are a dominant source of IL-22
[7,14–16]. Other cells, including CD4+ Th1, Th17, Th22 cells,
CD8+ Tc17, Tc22 cells, and cd T cells and NK cells can also
produce IL-22 [17–21]. Interestingly, IL-22R1, a subunit of IL-22
receptor, is only found in tissue epithelial cells, such as skin,
pancreas, intestine, liver, lung and kidney, which determines the
tissue specificity of the biological effects of IL-22 [7,11]. In murine
lung, IL-22Ra1 is expressed in the conducting airway in both
ciliated and non-ciliated cells [22]. Activation of proliferative and/
or anti-apoptotic genes may be the main mechanisms mediating
IL-22 immune responses. Signaling pathways, including Jak-
STAT-particularly STAT3, MAPK-Akt, and bcl-2, have been
found as critical downstream pathways for IL-22 functions
[17,23,24]. IL-22 has been shown to play a key role in controlling
bacteremia in experimental gram-negative pneumonia [25] and
airway repair after influenza infection [22].
In clinical studies, IL-22 expression has been found to be
elevated in the blood of asthmatic patients, which correlates with
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the disease severity [26]. Also, increased levels of IL-22 were found
in the serum of asthmatic patients and in the lung tissues in
experimental asthma in mice [27]. Accumulating evidence
indicates that IL-22 may have immune modulatory effects on
the development of allergen-induced pulmonary inflammation.
However, the findings from different studies were controversial
[27–29]. To further understand the role of IL-22 in allergic
asthma, we developed inducible transgenic mice that express IL-
22 specifically in the airways to investigate the immune
modulatory effects of this cytokine and its underlying mechanisms
in the context of OVA-induced lung inflammation.
Materials and Methods
Generation of inducible lung-specific IL-22 transgenic
mice
IL-22 transgenic mice were generated as described previously
[30] and more details are in the Supporting Information (Figure
S1 and Figure S2). The DNA fragment containing the TRE-
Tight (Clontech) promoter, IL-22 cDNA, and the SV40 polyad-
enylation signal was prepared and microinjected into pronuclei.
TRE-Tight-IL-22 mice were identified and crossbred with the
CC10-rtTA or SPC-rtTA transgenic mice [31,32] (kind gifts from
Dr. Jeffrey Whitsett, the University of Cincinnati) to produce
CC10-rtTA-IL-22 or SPC-rtTA-IL-22 double Tg(+) mice. Tg(2)
or wild type (WT) littermates were used as controls. In this study
terms Tg(2) and WT are interchangeable. All mice were on
C57BL/6 genetic background. Studies on animals were approved
by the IACUC of the Johns Hopkins University.
Induction of IL-22 expression in the lung
The IL-22 transgene was not activated until the mice were 4
weeks old. Doxycycline (Dox) was added to the animal’s drinking
water (0.5 mg/ml with 4% sucrose) [33]. For all experiments,
Tg(+) and WT littermates were randomized to receive normal or
Dox water for 4 weeks and OVA sensitization and challenge were
performed as described below.
OVA-induced allergic asthma
Allergen sensitization and challenge were carried out as
previously described [34]. Briefly, 4 weeks after Dox induction
mice were divided into four groups: WT mice-PBS, WT mice-
OVA, IL-22 Tg(+) mice-PBS, and Tg(+) mice-OVA. Sensitization
was started by i.p. injection of 50 mg of OVA (Grade V, Sigma-
Aldrich, St. Louis, MO) mixed with Alum (2 mg in 200 ml of PBS)
on day 0 and day 7. The mice were challenged intranasally (i.n.)
with 50 mg OVA on days 14, 15, and 16, pulmonary function tests
(PFT) were performed on day 17, and sacrifice on day 18. Serum
samples, bronchoalveolar lavage (BAL) fluids and cells, draining
lymph nodes (DLN) and lung tissues were collected and stored
until evaluation.
Assessment of pulmonary physiology
Pulmonary function tests (PFT) were performed 24 hours after
last OVA challenge [34]. Briefly, mice were anesthetized and,
through a cannula, connected to FlexiVent (SCIREQ, Montreal,
PQ, Canada) and mechanically ventilated. Lung resistance was
measured by using the forced oscillation technique [35]. Airway
hyperresponsiveness (AHR) to increasing doses of inhaled Metha-
choline (MCh) was determined. Data were collected at 1-minute
intervals and the values for lung resistance (cm H2O/ml/s) were
plotted as a function of MCh doses.
Lung and bronchoalveolar lavage samples
Lung tissue and BAL samples were obtained as previously
described [34,35]. Briefly, mice were anesthetized and a small-
caliber tubing was inserted into the trachea. Two successive
volumes of 1 ml of PBS were instilled, aspirated and pooled. BAL
samples were centrifuged at 4000 rpm, and supernatants were
stored at 280uC until evaluation. Cells in 100 ml aliquots were
counted by trypan blue staining. A total of 100,000 viable BAL
cells were centrifuged in Cytospin 3 (Thermo Shandon Ltd,
Runcorn, UK). Cell differentiation was determined by Diff-quik
(Fisher Scientific Co., Newark, DE). The lung was perfused with
cold PBS. The whole lung was either excised for RNA and protein
analyses or inflated with neutral buffered formalin for histology.
Histology, immunohistochemistry (IHC), and
immunofluorescence
H&E and Alcian blue (AB) stains were performed on lung
sections as described [35]. For IHC, monoclonal antibody against
eosinophil specific major basic protein (anti-MBP, a kind gift from
Drs. Nancy and James J. Lee, Mayo Clinic, Scottsdale, AZ) was
used (1:500) for eosinophils and anti-IL-22 antibody was used to
detect IL-22 (1:180). ABC staining kits were used to amplify the
signal (Santa Cruz Biotechnology). Immunofluorescence of p-
STAT3 was performed with rabbit anti-mouse phospho-Stat3
(Tyr705) (Cell Signaling, Danvers, MA) and Alexa Fluor 488-
labeled donkey anti-rabbit IgG as secondary antibody (Invitrogen)
and DAPI for nuclei. Tissue sections were mounted and examined
using Zeiss LSM 510 laser scanning confocal microscope (Carl
Zeiss) at 350 nm to assess p-STAT3 and 405 nm to assess cell
nuclei.
Analysis of mRNA
Total cellular RNA from lung tissue was collected and analyzed
by RT-PCR using specific primers for IL-22 and b-actin as
detailed in Supporting Information (Figure S1 and Figure S2).
Cytokine production by lymphocytes from draining
lymph nodes (DLN) and spleen
Lymphocytes from DLN (mediastinal and hilar) and purified
splenic CD4+ cells were cultured in RPMI1640 medium (5% FCS)
and were stimulated with medium as control, OVA (50 mg/ml) for
5 days or anti-CD3/CD28 (BD Bioscience) (5 mg/ml) for 3 days.
Supernatants were collected for cytokine measurement.
Quantification of cytokines, chemokines, and
immunoglobulins
Cytokines and chemokines in the BAL or supernatant from
lymphocytes were determined using commercially available
ELISA kits according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN; eBioscience, San Diego, CA). Serum
samples in duplicates were analyzed using ELISA kits for total and
specific IgE, IgG1, and IgG2a (BD Biosciences, San Jose, CA) per
manufacturer’s instructions.
Western blot
Rabbit anti-mouse STAT3 and phospho-STAT3 (Tyr705)
monoclonal antibodies (Cell Signaling, Fremont, CA) were used
as primary Abs (Neomarker). An anti-rabbit IgG conjugated to
HRP was used as secondary Ab (Santa Cruz Biotechnology).
Protein detection was accomplished with a Super Signal West
Femto Maximum Kit (Pierce).
IL-22 Modulates Allergic Asthma
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Statistical analysis
The Student t-test was used to determine the significance of
difference between two groups, and one-way ANOVA was used
for comparison among multiple groups. Data were expressed as
Mean6SEM and differences with P values =,0.05 were consid-
ered statistically significant.
Results
Generation of lung-specific inducible IL-22 transgenic
mice
Studies show that transgenic mice with liver overexpression of
IL-22 survived but lymphoid lineage-specific overexpression of IL-
22 caused neonatal mortality [36,37]. To avoid potential lethality,
an inducible transgenic approach was taken to overexpress IL-22
in the lung. As illustrated in Figure S1, we generated mice
carrying transgenes CC10-rtTA or SPC-rtTA and TRE-Tight-IL-
22 (CC10-rtTA-IL-22) or (SPC-rtTA-IL-22) and these mice were
used in the OVA-induced asthma experiments. The CC10 and
SPC promoter controlled rtTA is activated only in the presence of
Dox. To express IL-22 only in the adult mice, Dox water was not
given to Tg(+) mice and Tg(2) littermates until they were 4 weeks
of age (Figure S2). Inducible tissue-specific expression of IL-22 in
the airways was tested after 4 weeks of Dox and the induction was
kept on for the entire experiment. Without Dox water, IL-22 was
not detected either at the mRNA or protein level in any tissue of
Tg(+) and Tg(2) mice (Figures 1A–C). However, after Dox
induction for 4 weeks, IL-22 mRNA was readily detected in the
lung tissue and IL-22 protein was elevated in the bronchoalveolar
lavage (BAL) fluid of Tg(+) mice but not in Tg(2) mice by ELISA
(Figure 1A, 1B). Immunohistochemistry (IHC) using anti-IL-22
was performed to confirm that the location of IL-22 expression
was in the large airways in CC10-rtTA-IL-22 mice and in the
small airways in SPC-rtTA-IL-22 mice (Figure 1C). These results
demonstrated that using the CC10-rtTA or SPC-rtTA system, the
IL-22 transgene was targeted specifically in the airways in an
inducible fashion.
Activation of STAT3 by IL-22 expressed in the lung
To determine whether IL-22 expressed in the airways was
biologically active, activation of its downstream signaling molecule
STAT3 was tested. Using immunofluorescence (IF), we demon-
strated that inducible IL-22 activated p-STAT3 in the airways of
Tg(+) mice compared to background staining in Tg(2) mice
(Figure 2A). By Western blot, p-STAT3 was found to be
increased in the lung tissues of Tg(+) mice compared to Tg(2)
mice at baseline (with PBS) (Figure 2B). OVA sensitization and
challenge induced increased p-STAT3 above baseline in Tg(2)
mice but p-STAT3 was further increased in Tg(+) mice
(Figure 2C). These results indicate that inducible IL-22 expres-
sion activated its signaling pathway in the airway epithelial cells
and OVA stimulation further increased p-STAT3.
Protective effect of IL-22 on allergic airway inflammation
To verify directly whether IL-22 has any modulatory effect on
allergen induced lung inflammation, Tg(2) and IL-22 Tg(+) mice
were sensitized on days 0 and 7 with OVA, followed by three
OVA challenges through the airway on days 14, 15 and 16. In
PBS control groups, Tg(2) and IL-22 Tg(+) mice showed no
airway inflammation or eosinophilia. Similar to what we had
observed in non-allergen challenged mice, IL-22 levels in the BAL
were elevated in IL-22 Tg(+) mice (Figure 3A). After OVA
sensitization and challenge, both Tg(2) and Tg(+) groups showed
significantly increased BAL cells compared to PBS challenged
control groups. However, no difference was noticed in the total
BAL cell numbers between the two Tg(2) and Tg(+) OVA groups
(Figure 3B). In cell differential counts, OVA stimulated Tg(2)
group (OVA/Tg(2)) showed substantial eosinophilic airway
inflammation, while the number of eosinophils in the BAL of
OVA treated IL-22 Tg(+) (OVA/Tg(+)) group was significantly
less compared to the OVA/Tg(2) group (Figure 3C). Eosinophil
infiltration in the lung tissue (H&E) also showed a reduction in the
OVA/Tg(+) group compared to the OVA/Tg(2) group (Fig-
ure 3D). IHC analysis of eosinophil-specific MBP in the tissue
confirmed the reduction of eosinophils in the lung tissue of OVA/
Tg(+) mice vs. OVA/Tg(2) mice (Figure 3D). Mucus metaplasia
is another important feature of allergic asthma. Analysis using
Alcian Blue staining of lung sections showed that IL-22 Tg(+) mice
had less mucus producing cells in the airways than Tg(2) mice
after OVA stimulation (Figure 3D). CC10-IL-22 mice showed
similar results (data not shown). These results demonstrated that
IL-22 has protective effects on OVA induced allergic airway
inflammation (Figure 3).
IL-22 alleviates OVA induced airway hyperresponsiveness
Analysis of the lung mechanics using the forced oscillation
technique (FlexiVent) demonstrated that, in the absence of OVA
at baseline, IL-22 Tg(+) mice did not show any significant
difference in lung resistance compared to that of Tg(2) mice
(Figure 4). After OVA challenge, as expected, in response to
increasing doses of MCh, Tg(2) mice showed large increments in
lung resistance above baseline. However, IL-22 Tg(+) mice that
received OVA showed significantly reduced lung resistance at
MCh concentrations above 6.25 mg/ml. Similar results were seen
in CC10-rtTA-IL-22 and SPC-rtTA-IL-22 mice (Figure 4A, 4B).
These data indicate that IL-22 in the airways protects mice from
allergen induced airway hyperresponsiveness.
Lung-specific expression of IL-22 did not affect OVA-
induced immunoglobulin responses
To determine whether inducible IL-22 expression in the lung
has any effect on the systemic immune response in allergen-
induced inflammation, serum samples were obtained and total and
OVA-specific immunoglobulins, IgE, IgG1 and IgG2a, in the
serum were measured by ELISA. Mice received PBS had only
baseline total immunoglobulins in the serum without any allergen-
specific IgE or IgGs. OVA induced elevated total and OVA-
specific IgE, IgG1 and IgG2a in the serum of Tg(2) and SPC-IL-
22 Tg(+) mice (Figure 5). However, no significant difference was
noted between IL-22 Tg(+) and Tg(2) mice that received OVA.
CC10-IL-22 mice showed similar results (data not shown). These
results indicate that inducible IL-22 expression in the airway
epithelial cells had no effect on immunoglobulin responses.
Effect of IL-22 on cytokine and chemokine expression in
the lung
We next examined whether the inhibitory effect of IL-22 on
OVA-induced allergic airway inflammation was through regula-
tion of inflammatory mediators, such as cytokines and chemokines
that control cell migration. BAL samples were collected after OVA
challenge for cytokine and chemokine measurement. Overall,
OVA stimulation induced elevated levels of cytokines and
chemokines above the baseline in PBS groups. Compared to
OVA/Tg(2) mice, OVA/CC10-IL-22 Tg(+) mice showed signif-
icantly lower levels of IL-13, but not IL-4, in the BAL. Th1
cytokine, IFN-c, showed a slight increase in OVA treated groups
compared to the PBS groups, but no statistical difference was
IL-22 Modulates Allergic Asthma
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noted between Tg(2) and Tg(+) mice. There was also a trend of
reduction in IL-17A and eotaxin in Tg(+) mice, but the difference
between Tg(+) and Tg(2) mice was not statistically significant
(Figure 6). SPC-IL-22 mice showed similar results (data not
shown).
Figure 1. Targeted IL-22 expression in the airway epithelial cells. (A) IL-22 mRNA expression in the lung of Tg(+) mice after being given
doxycycline (Dox) water for 4 weeks compared to Tg(2) mice. (B) IL-22 protein in the BAL samples expressed by airway epithelial cell was measured
by ELISA. Both SPC-IL-22 and CC10-IL-22 Tg(+) mice showed much higher levels of IL-22 compared to Tg(2) mice (P,0.0001). (C) Identification of
localization of IL-22 expression by IHC in the airway epithelial cells. In CC10-IL-22 mice IL-22 was mainly expressed in the large airways, whereas in
SPC-IL-22 mice, mainly in the small airways.
doi:10.1371/journal.pone.0107454.g001
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IL-22 inhibition of cytokine production by local
lymphocytes, but not splenocytes
To determine if IL-22 inhibition of airway allergic inflammation
was associated with systemic or local immune responses, spleno-
cytes and lymphocytes from DLN of Tg(+) and Tg(2) mice after
OVA stimulation were isolated and cultured. After stimulation
with OVA or anti-CD3/CD28 supernatant was collected and
cytokines IL-13 and IFN-c were measured by ELISA. At baseline,
cells cultured in media alone did not show any cytokine. We also
did not observe cytokine responses in immune cells from PBS
groups in response to OVA stimulation. OVA sensitized
splenocytes and DLN lymphocytes from Tg(2) mice showed
robust responses to antigen and TCR stimulation by producing
IL-13 and IFN-c. However, DLN lymphocytes, but not spleno-
cytes, from IL-22 Tg(+) mice produced significantly lower levels of
IL-13 compared to cells from Tg(2) mice. (Figure 7A, 7B).
There was no difference between cells from Tg(+) and Tg(2) mice
in IFN-c production in response to OVA or anti-CD3/CD28
(Figure 7C, 7D). CC10-IL-22 mice showed similar results (data
not shown). These results showed that IL-22 alleviated airway
Figure 2. Activation of p-STAT3 by IL-22 in the lung of Tg(+) mice. (A) Phospho-STAT3 protein expression activated by IL-22 in the airway
epithelial cells of IL-22 Tg(+) mice and compared to background level in Tg(2) mice using immunofluorescence (IF). (B) Phospho -STAT3 protein
expression in the lung tissue of IL-22 Tg(+) and Tg(2) mice detected by Western blot using anti-p-STAT3 antibody. (C) Phospho-STAT3 protein
expression in the lung tissues of OVA-stimulated IL-22 Tg(+) and Tg(2) mice detected by Western blot.
doi:10.1371/journal.pone.0107454.g002
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allergic inflammation possibly through inhibition of the local Th2
immune response.
Discussion
Allergic asthma is a Th2 dominant inflammatory disease in the
airways. In recent years, another T cell subtype, Th17/Th22, has
been added to this paradigm. Recent studies suggested that Th17/
Th22 cytokines IL-17 and IL-22 have regulatory effects on allergic
airway inflammation. Besides its proinflammatory effects in
autoimmune diseases and host defense, IL-17 can recruit
neutrophils into the airways in allergic asthma [38]. After IL-22
was first described [39], extensive studies have shown that IL-22
has immunological effects, predominantly proinflammatory, in
various diseases or models, such as bleomycin induced lung
inflammation, and other disease models, including arthritis,
hepatitis, psoriasis, atopic dermatitis, and inflammatory bowel
disease [11,40–45]. In the lung, IL-22 plays a key role in
controlling bacteremia in experimental gram-negative pneumonia
and airway tissue repair after influenza infection [22,25].
Currently, Phase I and Phase II clinical trials based on anti-IL-
22 therapies are on going for atopic dermatitis, psoriasis, and
rheumatoid arthritis. However, IL-22 related therapies for the
treatment of allergic asthma have not been initiated. One possible
Figure 3. IL-22 alleviated OVA-induced eosinophilic inflammation in the lung. (A) High levels of IL-22 cytokine were seen in the BAL of PBS
and OVA-stimulated IL-22 Tg(+) mice without difference between the two groups (P.0.05). When compared to Tg(2) mice, IL-22 concentrations in
the BAL of Tg(+) mice were much higher than that in PBS and OVA-stimulated control groups (P,0.0001). (B, C) BAL total cell and differentials counts
showed that OVA-stimulated IL-22 Tg(+) group had a much higher percentage of eosinophils compared to OVA-stimulated Tg(2) mice (P,0.0001),
but there is no difference in the total cell counts (P.0.05). (D) Lung histology of OVA-induced allergic asthma in SPC-IL-22 Tg(+) mice and Tg(2) mice,
H&E, IHC for MBP, and Alcian blue staining showed that OVA-induced IL-22 Tg(2) group had much more severe airway inflammation compared to
OVA-induced IL-22 Tg(+) group.
doi:10.1371/journal.pone.0107454.g003
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reason is that the role of IL-22 in allergic asthma is not well
defined. This is at least in part due to a lack of studies that have
focused on the immunological effects of IL-22 on allergic airway
inflammation and the findings from several studies are inconsis-
tent. Some evidence suggested that IL-22 acts as a proinflamma-
tory cytokine like IL-17, but others pointed to the opposite
direction, in that IL-22 may be protective in allergic airway
inflammation. The discrepancies may be caused by differences in
the model systems and approaches used in these studies. For
example, administration of recombinant murine IL-22, use of
neutralizing IL-22 antibody or IL-22 plasmid DNA during
sensitization or challenge phase as well as IL-22 knockout mice
were used in allergen induced allergic asthma models. However,
no study has been performed to show the direct tissue effects of IL-
22 in the lung and whether IL-22 expressed in the airways has
regulatory effects on allergen induced asthma. To further
understand IL-22 in allergic asthma, we generated transgenic
mice that express the cytokine specifically in the airway epithelial
cells and investigated the immune modulating effects of IL-22 in
OVA allergen induced allergic asthma.
Using the tetracycline inducible transgenic system, we estab-
lished IL-22 mouse models with two different promoters, SPC and
CC10, to target the expression of this cytokine in the small and
large airways, respectively. The location and quantification of IL-
22 expression were determined by IHC and ELISA. Without Dox
induction, no IL-22 was detected in the airways. But when
induced by Dox, IL-22 protein was readily detectable in the
airways and in the lung tissue.
IL-22 signals through the Jak-STAT pathway, phosphorylating
and activating kinases Jak1 and Tyk2 and downstream transcrip-
tion factors STAT1, STAT3 and STAT5. Indeed, when IL-22
transgene was turned on by Dox, p-STAT3 was detected by IHC
and Western blot in the airways of transgene positive mice,
indicating that IL-22 is functional in the lung epithelial cells. In
Figure 4. IL-22 attenuated airway hyperresponsiveness (AHR). (A, B) Invasive PFT of OVA stimulated IL-22 Tg(+) and Tg(2) mice was assessed
(FlexiVent, SciQuest). Lung resistance at baseline and in response to increasing concentrations of methacholine (MCh) through inhalation was
recorded and analyzed (*P,0.05). The number of animals used in each group was as indicated. Data represented as Mean6SEM. OVA-induced IL-22
Tg(+) mice showed significantly lower lung resistance compared to OVA-induced IL-22 Tg(2) mice.
doi:10.1371/journal.pone.0107454.g004
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addition, OVA stimulation induced p-STAT3 in the airways in
both WT and IL-22 Tg(+) mice but higher levels of p-STAT3 were
maintained in the Tg(+) mice throughout the experiments.
In the present study, OVA sensitization and challenge did not
induce detectable endogenous IL-22 expression in the airway of
the mice. This finding is consistent with one report [4] but
different from another, in which IL-22 expression was found
increased in the OVA model [27]. However, in the latter study IL-
22 was detected in the supernatant of PMA and ionomycin
stimulated mononuclear cells isolated from the lungs of OVA
treated mice. No direct detection of IL-22 in the BAL or lung
tissue was reported.
In this study IL-22 expression was activated by Dox for 4 weeks
before OVA sensitization and the transgene was kept on for the
rest of the experiment. Thus, the IL-22 cytokine was present in the
lung throughout OVA sensitization and challenge. IL-22 trans-
genic mice showed decreased eosinophils in the BAL and a
significant reduction in eosinophilic inflammation in the lung,
decreased mucus metaplasia in the airways and functionally,
reduced airway hyperresponsiveness. These results were similar to
those in studies by two other groups [27,46]. They used IL-22
knockout mice and Balb/c mice to establish OVA-induced allergic
airway inflammation and gave different treatment during different
phases [27,46]. IL-22 is produced by many immune cells.
However, the expression of functional IL-22 receptor is restricted
to nonhematopoietic tissue cells in the skin, pancreas, intestine,
liver, lung and kidney. It’s known that IL-22 does not induce
immunoglobulin production by human B cells [47]. In our study,
the IL-22 transgene was targeted specifically in the lung.
Measurement of serum immunoglobulins showed no difference
between IL-22 Tg(+) mice and WT mice after OVA stimulation,
indicating that IL-22 in the lung has no effect on immunoglobulin
responses. This finding is different from a previous report in which
OVA-specific IgE was decreased when recombinant IL-22 was
given at the time of OVA challenge [27]. The reason for this
discrepancy is unclear. It could be due to a much higher dose of
IL-22 used in that study (1 mg/mouse, 3x), whereas the transgenic
expressed IL-22 in our system was probably lower, even though
IL-22 was present continuously.
Measurement of the cytokines and chemokines in the lung
showed a significant reduction in IL-13 and a slight decrease in IL-
4, eotaxin and a trend of reduction in IL-17A, but not IFN-c, in
Figure 5. Serum immunoglobulin levels in OVA-induced allergic asthma in IL-22 Tg(+) (SPC-IL-22) and Tg(2) mice. Serum samples
from IL-22 Tg(+) and Tg(2) mice were collected 48 hours after last OVA challenge. Immunoglobulins, including total and OVA-specific IgE, IgG1 and
IgG2a were measured by ELISA and analyzed by one-way ANOVA. Data from individual animals were plotted. Both IL-22 Tg(+) and Tg(2) group
showed much higher level either in total or in OVA-specific IgE, IgG1 and IgG2a than PBS treatment groups (P,0.01). But there is no difference
between IL-22 Tg(+) and Tg(2) groups (P.0.05).
doi:10.1371/journal.pone.0107454.g005
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Figure 6. Effect of IL-22 (CC10-IL-22) on cytokine and chemokine production in OVA-induced allergic asthma. Th1 cytokine, IFN-c, and
Th2 cytokines, IL-4 and IL-13, Th17 cytokine IL-17A, and chemokine eotaxin in the BAL were measured by ELISA. The number of animals in each group
was indicated and data were shown as Mean6SEM. **P,0.01 (unpaired Student t-test).
doi:10.1371/journal.pone.0107454.g006
IL-22 Modulates Allergic Asthma
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IL-22 transgenic mice, suggesting that IL-22 down-regulates T-cell
priming in the lung. Interestingly, however, IL-22 did not affect
the generation of OVA-specific antibodies suggesting that IL-22
did not impact germinal center reactions. Notably, when looking
into the modulatory function of IL-22 on the immune cells, we
found no difference between WT and IL-22 mice in splenocyte
production of IFN-c, IL-4 and IL-13 in response to OVA allergen
or CD3/CD28 TCR stimulation. In lymphocyte cytokine
production, however, a significant reduction in IL-13 was
observed, but not other cytokines, by cells from IL-22 transgenic
mice. Together with the IgE data, these results indicate that IL-22
in the lung suppressed immune cell production of IL-13 and Th2
cytokines and chemokines in the lung without any effect on the
systemic immune responses.
Taking the transgenic approach, we sought to understand the
functional role of IL-22 in the lung in the context of allergen-
induced asthma. IL-22 was continuously and consistently
expressed in the small and large airways in mice. IL-22 was able
to activate downstream signaling molecule STAT3 without
inducing any discernable pathological changes in the lung.
However, in the context of allergen-induced asthma, IL-22
suppressed eosinophilic inflammation, mucus hyperplasia, AHR,
and Th2 cytokine and chemokine production without affecting the
systemic immune responses. With this feature IL-22 may be
considered as an immune modulator in allergic asthma. Further
studies are required to elucidate the underlying mechanisms for
the effects of IL-22 in the lung.
Supporting Information
Figure S1 Schematic DNA construct of TRE-Tight-IL-22
transgene. IL-22 cDNA was inserted into the multiple cloning
site (MCS) of pTRE-Tight vector (Clontech) using restriction
enzymes and microinjected into fertilized eggs as described.
(TIF)
Figure S2 Generation of SPC- or CC10-rtTA-TRE-Tight-
IL-22 (also called SPC- or CC10-IL-22) mice. As illustrated,
SPC-rtTA or CC10-rtTA mice were crossbred with TRE-Tight-
IL-22 mice to obtain SPC- or CC10-IL-22 double positive mice.
The IL-22 transgene was activated by doxycycline (Dox) in the
drinking water for 4 weeks. ELISA, Western blot, immunohisto-
chemistry (IHC) and immunofluorescence (IF) were performed to
identify the expression of IL-22 in the lung. Without Dox, no IL-
22 was detected in the BAL or in the lung.
(TIF)
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